These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 8475950)

  • 41. Mobilization of lead by calcium disodium edetate. A reappraisal.
    Chisolm JJ
    Am J Dis Child; 1987 Dec; 141(12):1256-7. PubMed ID: 3120574
    [No Abstract]   [Full Text] [Related]  

  • 42. Disappearance of immune deposits with EDTA chelation therapy in a case of IgA nephropathy.
    Lin JL; Lim PS
    Am J Nephrol; 1992; 12(6):457-60. PubMed ID: 1292346
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Hyperuricemia due to renal failure, autosomal dominant polycystic kidney disease and lead nephropathy].
    Hosoya T
    Nihon Rinsho; 2003 Jan; 61 Suppl 1():294-8. PubMed ID: 12629734
    [No Abstract]   [Full Text] [Related]  

  • 44. [Gout and hyperuricemia associated with lead poisoning].
    Lejeune E; Tolot F; Meunier P
    Rev Rhum Mal Osteoartic; 1969 Apr; 36(4):161-73. PubMed ID: 5402943
    [No Abstract]   [Full Text] [Related]  

  • 45. Chelated lead and bone lead.
    Tell I; Somervaille LJ; Nilsson U; Bensryd I; Schütz A; Chettle DR; Scott MC; Skerfving S
    Scand J Work Environ Health; 1992 Apr; 18(2):113-9. PubMed ID: 1604271
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Heavy Metal Toxicity in Chronic Renal Failure and Cardiovascular Disease: Possible Role for Chelation Therapy.
    Glicklich D; Shin CT; Frishman WH
    Cardiol Rev; 2020; 28(6):312-318. PubMed ID: 32040019
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The clinical differentiation of lead gout from primary gout.
    Emmerson BT
    Arthritis Rheum; 1968 Oct; 11(5):623-34. PubMed ID: 5680985
    [No Abstract]   [Full Text] [Related]  

  • 48. Environmental exposure to lead and progressive diabetic nephropathy in patients with type II diabetes.
    Lin JL; Lin-Tan DT; Yu CC; Li YJ; Huang YY; Li KL
    Kidney Int; 2006 Jun; 69(11):2049-56. PubMed ID: 16641918
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Saturnine gout: a review of 42 patients.
    Halla JT; Ball GV
    Semin Arthritis Rheum; 1982 Feb; 11(3):307-14. PubMed ID: 6821383
    [No Abstract]   [Full Text] [Related]  

  • 50. Fatal nephropathy during edathamil therapy in lead poisoning.
    BRUGSCH HG
    AMA Arch Ind Health; 1959 Oct; 20():285-92. PubMed ID: 13805211
    [No Abstract]   [Full Text] [Related]  

  • 51. [Acute renal failure in the course of occupational lead intoxication. Chelation therapy responsability (author's transl)].
    Yver L; Maréchaud R; Picaud D; Touchard G; d'Eyzac AT; Matuchansky C; Patte D
    Nouv Presse Med; 1978 May; 7(18):1541-3. PubMed ID: 97624
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Irregular gout.
    Dhaon P; Wakhlu A; Dhakad U
    Int J Rheum Dis; 2014 Mar; 17(3):351-3. PubMed ID: 24237618
    [No Abstract]   [Full Text] [Related]  

  • 53. Triglyceride concentrations in primary gout and gout of chronic lead nephropathy.
    Emmerson BT; Knowles BR
    Metabolism; 1971 Aug; 20(8):721-9. PubMed ID: 5568414
    [No Abstract]   [Full Text] [Related]  

  • 54. Elevated lead burden in Chinese patients without occupational lead exposure.
    Lin JL; Lim PS
    Miner Electrolyte Metab; 1992; 18(1):1-5. PubMed ID: 1406500
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Lead nephrotoxicity and associated disorders: biochemical mechanisms.
    Nolan CV; Shaikh ZA
    Toxicology; 1992; 73(2):127-46. PubMed ID: 1319092
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Chelation therapy for patients with elevated body lead burden and progressive renal insufficiency. A randomized, controlled trial.
    Lin JL; Ho HH; Yu CC
    Ann Intern Med; 1999 Jan; 130(1):7-13. PubMed ID: 9890856
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Purine metabolism in patients with gout: the role of lead.
    Miranda-Carús E; Mateos FA; Sanz AG; Herrero E; Ramos T; Puig JG
    Nephron; 1997; 75(3):327-35. PubMed ID: 9069456
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Lead gout].
    Lebedeva MV; Balkarov IM; Shovskaia TN; Nikiforova NV
    Klin Med (Mosk); 1995; 73(3):103-4. PubMed ID: 8577091
    [No Abstract]   [Full Text] [Related]  

  • 59. Low-level environmental exposure to lead and progressive chronic kidney diseases.
    Lin JL; Lin-Tan DT; Li YJ; Chen KH; Huang YL
    Am J Med; 2006 Aug; 119(8):707.e1-9. PubMed ID: 16887418
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The role of lead in gout nephropathy reviewed: pathogenic or associated factor?
    Miranda ME; Puig JG; Mateos FA; Ramos TH; Herrero E; González A; Gil A; Vázquez JO
    Adv Exp Med Biol; 1991; 309A():209-12. PubMed ID: 1789210
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.